As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer review
Call for Papers:
Viral Emerging and Re-emerging Infectious Diseases
We invite authors to submit original research and review articles that focus on or illuminate aspects of the epidemiology, clinical, diagnostics, therapeutics and prevention of viral emerging and Re-emerging infectious diseases.
Currently open for submissions
Guest Editor - Alfonso J. Rodriguez-Morales
Call for Papers
Spatial inequality, infectious diseases and disease control
We invite authors to submit original research and review articles that focus on emerging infectious diseases in humans and animals and brings together research that investigates the relationship between spatial inequalities and the impact and prevalence of infectious diseases.
Articles
-
-
Nomogram to predict multidrug-resistant tuberculosis
-
Coagulase-negative staphylococci (CoNS) as a significant etiological factor of laryngological infections: a review
-
Multi-drug resistant and extended-spectrum β-lactamases producing bacterial uropathogens among pregnant women in Northwest Ethiopia
-
Emerging high-risk ST101 and ST307 carbapenem-resistant Klebsiella pneumoniae clones from bloodstream infections in Southern Italy
-
The combination of decoy receptor 3 and soluble triggering receptor expressed on myeloid cells-1 for the diagnosis of nosocomial bacterial meningitis
-
Identification of Staphylococcus aureus: DNase and Mannitol salt agar improve the efficiency of the tube coagulase test
-
Treatment of Klebsiella Pneumoniae Carbapenemase (KPC) infections: a review of published case series and case reports
-
Are we aware how contaminated our mobile phones with nosocomial pathogens?
The Erratum to this article has been published in Annals of Clinical Microbiology and Antimicrobials 2009 8:31
-
New antibiotics for bad bugs: where are we?
Recent Blogs
Aims and scope
Annals of Clinical Microbiology and Antimicrobials considers good quality, novel and international research of more than regional relevance.
Research must include epidemiological and/or clinical information about isolates, and the journal covers the clinical microbiology of bacteria, viruses and fungi, as well as antimicrobial treatment of infectious diseases.
Editor profiles
Hakan Leblebicioglu, Editor-in-Chief
Professor Leblebicioglu is the former head of the Department of Infectious Diseases and Clinical Microbiology at Ondokuz Mayis University Medical School in Turkey and working at Samsun Liv Hospital, Turkey. He is currently a Fellow of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), a founding member and Honorary Chief of ESCMID Study Group for Infections in Travelers and Migrants (ESGITM) and also a member of the Study Group for Viral Hepatitis (ESGVH). He has authored 162 publications in peer-reviewed international medical journals (H index is 31 in Web of Science), mainly in Crimean Congo hemorrhagic fever, viral hepatitis and healthcare associated infections. He has conducted workshops and courses in the area of effective communication, presentation skills, proposal and manuscript writing.
Tim McHugh, Editor-in-Chief
Professor McHugh leads the UCL Centre for Clinical Microbiology (CCM). Located at the Royal Free Hospital, CCM aims to improve the diagnosis and treatment of infectious diseases and contributes in the areas of antimicrobial resistance, infection in patients with immunosuppression and hospital acquired infection. Prof McHugh has a particular focus on respiratory infection and CCM has activities in all stages of the TB drug development pathway with projects on evaluation of new compounds as well as supporting the laboratory aspects of clinical trials. An underlying theme is the development of biomarkers of treatment outcome, whether transcriptomic analysis of in vitro treatments or the more complex picture of monitoring outcome in patients.
Annual Journal Metrics
-
Speed
92 days to first decision for reviewed manuscripts only
37 days to first decision for all manuscripts
131 days from submission to acceptance
13 days from acceptance to publicationCitation Impact
2.924 - 2-year Impact Factor
3.032 - 5-year Impact Factor
1.367 - Source Normalized Impact per Paper (SNIP)
1.060 - SCImago Journal Rank (SJR)Usage
356,195 Downloads
264 Altmetric Mentions
